Related Experiment Video
Updated: Jun 13, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor XIII and atherothrombotic diseases
László Muszbek1, Zsuzsanna Bereczky, Zsuzsa Bagoly
1University of Debrecen, Medical and Health Science Center, Debrecen, Hungary. muszbek@med.unideb.hu
Seminars in Thrombosis and Hemostasis
|April 15, 2010
Summary
Factor XIII (FXIII) strengthens blood clots and regulates fibrinolysis. Recent research explores its less understood role in atherothrombotic diseases, including coronary artery disease and stroke risk.
Area of Science:
- Biochemistry
- Hematology
- Cardiovascular Science
Background:
- Factor XIII (FXIII) is a crucial enzyme in hemostasis, cross-linking fibrin to stabilize clots.
- FXIII also inhibits fibrinolysis, protecting clots from premature breakdown.
- While FXIII deficiency causes bleeding, its role in thrombosis is less defined.
Purpose of the Study:
- To review recent findings on the association between Factor XIII and atherothrombotic diseases.
- To explore the link between FXIII levels, polymorphisms, and the risk of cardiovascular events.
Main Methods:
- Literature review focusing on studies from the last decade.
- Analysis of data on FXIII's involvement in atherogenesis and specific vascular diseases.
Main Results:
- FXIII plays a significant role in clot stabilization and fibrinolysis regulation.
- Emerging evidence suggests a link between FXIII activity/genetics and atherothrombotic disease risk.
- Data on FXIII's contribution to coronary artery disease, ischemic stroke, and peripheral artery disease is accumulating.
Conclusions:
- Factor XIII is a key factor in both hemostasis and potentially atherothrombosis.
- Further research is needed to clarify FXIII's precise role and therapeutic potential in thrombotic disorders.
- Understanding FXIII's association with atherothrombotic diseases may offer new insights into disease risk stratification.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.